IVF

INVO Fertility, Inc. (INVO Bioscience, Inc.) - 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for the period ended June 30, 2009. INVO Bioscience, Inc. is a development-stage company commercializing the INVOcell, a patented device designed to provide a lower-cost alternative to in-vitro fertilization (IVF). The company received CE Marking in May 2008, allowing sales in the European Economic Area and other regions, but is still seeking FDA clearance for the U.S. market. As of the reporting date, the company had approximately 53.8 million shares of common stock outstanding.

Key Financial Metrics

Debt and Liquidity: The company holds a $50,000 line of credit with Century Bank (fully utilized). It also has related party notes totaling $184,462 ($88,000 current, $96,462 long-term). Cash used in operating activities for the six months ended June 30, 2009, was $348,634.

Material Changes vs. Prior Period

• Revenue: Revenue increased from $0 in the prior year periods to $16,630 (Q2) and $53,445 (YTD) due to the commencement of international shipments to distributors and physicians.
• Expenses: Selling, General, and Administrative (SG&A) expenses surged to $444,103 for Q2 2009 (up from $256,522 in Q2 2008) and $1.1 million YTD. This increase is attributed to hiring full-time staff, increased travel for international market expansion, and costs associated with being a public company.
• Loss: Net loss widened significantly to $(438,731) for Q2 2009 compared to $(275,969) in Q2 2008, driven by higher operating expenses outpacing initial revenue generation.
• Liabilities: Accounts payable increased from $226,861 at year-end 2008 to $778,827 at June 30, 2009, indicating a reliance on trade credit to fund operations.

Outlook, Risks, and Management Commentary

Going Concern: The filing explicitly states that the company's recurring losses, negative cash flows, and working capital deficiency raise substantial doubt about its ability to continue as a going concern. The company requires approximately $175,000 per month to fund operations.

Capital Raising: Management is actively seeking up to $5 million in equity capital. To bridge immediate cash needs, the company initiated a $500,000 convertible bridge loan offering. As of July 15, 2009 (subsequent to the period end), the company closed the initial tranche of $100,000.

Operational Risks:

• Regulatory: No assurance is given regarding the timing or success of FDA 510(k) clearance, which is targeted for 2010.
• Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of June 30, 2009, due to limited resources and a lack of segregation of duties.
• Anti-Dilution: A recent convertible note issuance at $0.10 triggered anti-dilution clauses for prior investors, requiring the issuance of 1.125 million additional shares.

Investor Verification Checklist

• Cash Runway: Verify the status of the $500,000 bridge offering and the $5 million equity raise, as the company had only $82 in cash at period end.
• Related Party Transactions: Review the terms of the $184,462 in loans from the CEO and President, including interest rates and repayment schedules.
• Stock Subscription Receivable: Confirm the collection of the remaining $205,000 owed by Lionshare Ventures LLC, which is recorded as a contra-equity item.
• Internal Controls: Assess the progress in remediating the material weaknesses in internal controls over financial reporting.
• Revenue Sustainability: Evaluate whether the initial international sales ($53k YTD) are scalable given the high SG&A burn rate ($1.1M YTD).